Caris Life Sciences, Inc. (CAI) is a Biotechnology company in the Healthcare sector, currently trading at $20.19. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CAI = $31.30 (+55% from the current price, the stock appears undervalued). Analyst consensus target is CAI = $31 (+55.2% upside).
Valuation: CAI trades at a trailing Price-to-Earnings (P/E) of -460.7 (S&P 500 average ~25).
Financials: revenue is $812M, +50%/yr average growth. Net income is $538M (loss), growing at -26.6%/yr. Net profit margin is -66.2% (negative). Gross margin is 66.4% (+35.4 pp trend).
Balance sheet: total debt is $379M against $577M equity (Debt-to-Equity (D/E) ratio 0.66, moderate). Current ratio is 7.85 (strong liquidity). Debt-to-assets is 33.7%. Total assets: $1.1B.
Analyst outlook: 5 / 6 analysts rate CAI as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 70/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
